cholesterol lowering intervention

systematic review meta-analysis network meta-analysis

Select acute coronary syndromeacute myocardial infarctionaortic stenosisCABG surgerycardiovascular preventiondiabetes type 2familial hypercholesterolemia heart failurehypertensionperipheral vascular diseasespost myocardial infarctionpost stroke all chronical situationsAll type of patientDiabetic patientsdiabetic patients with or withour hypercholesterolemiauncoded clinical condition ***elderly patientshigh risk patients with or without LDL cholesterol elevationpatient with related diseasePatients with LDL elevation and without CHDpatients with other atherosclerotic localisationpatients with prior MI or with CHDpost stroke (or TIA)primary preventionsecondary preventionwomen       ACAT inhibitionCETP inhibitorcolestipol-niacincombination therapiesdietezetimibefibrateshormonesinhibitor of lipoprotein-associated phospholipaseniacinniacin (on top statin)other cholesterol lowering drugsPolicosanolProbucolresinsstatinsstatins high dosestatins+ezetimibestrategysurgery atorvastatincerivastatinfluvastatinlovastatinpravastatinrosuvastatinsimvastatinezetimibebezafibratefenofibratepolicosanolcholestyramineclofibratecolestipoldietestrogenetofibrategemfibrozilniacinpactimibeprobucolthyroxinetorcetrapib vs placebovs placebo or controlvs active treatmentvs angioplastyvs ezetimibevs statin       cerebral vascular diseaseearly initiationelderlyhypertensive patientskidney diseasesprimary preventionsecondary preventionsquamous NSCLCtype 2 diabetes

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (370)non cardiovascular death (195)stroke (fatal and non fatal) (189)Coronary death (188)Coronary event (186)cardiovascular events (165)cardiac death (156)Non fatal MI (150)Cardiovascular death (109)Rhabdomyolysis (79)Coronary death and non fatal MI (68)Death from cancer (65)MACE (62)Fatal stroke (56)new-onset diabetes (52)Revascularization (46)Fatal MI (42)Myopathy (40)Haemmorhagic stroke (35)Adverse events (30)cardiovascular events at 4 months (30)cardiovascular events at 1 month (30)Cancer (13)Non fatal stroke (12)myocardial infarction (fatal and non fatal) (9)Venous thromboembolism (6)CABG (6)recurrent angina (6)Non vascular death (6)atrial fibrillation (5)stroke or TIA (4)TIA (4)LDL (3)HDL (at 1 y) (3)total cholesterol (at 1 y) (3)Deaths or MI (3)PTCA (3)retinopathy (2)vision loss (2)Amputation (2)cardiac event (fatal and non fatal ) (2)End stage renal disease (2)Myocardial ischemia (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	non cardiovascular death
acute coronary syndrome
atorvastatin
MIRACL, 2001	atorvastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	suggesting
Colivicchi, 2002	atorvastatin	usual care	acute coronary syndrome	early initiation	Exploratory	negative
ESTABLISH, 2004	atorvastatin	usual care	acute coronary syndrome	early initiation	Exploratory	negative
PROVE IT - TIMI 22, 2004	atorvastatin	pravastatin	acute coronary syndrome	early initiation	Low risk of bias	suggesting
ezetimibe
IMPROVE-IT, 2014      NCT	ezetimibe	placebo (on top statins)		early initiation	Low risk of bias	conclusive
fluvastatin
LIPS (sub groups), 2002	fluvastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
FLORIDA, 2002	fluvastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
pravastatin
LAMIL, 1997	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
RECIFE, 1999	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
PAIS, 2001	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
PACT, 2004	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	suggesting
L-CAD, 2000	pravastatin	usual care	acute coronary syndrome	early initiation	Exploratory	suggesting
PTT, 2002	pravastatin	usual care	acute coronary syndrome	early initiation	Exploratory	suggesting
simvastatin
A to Z, 2004	simvastatin	placebo	acute coronary syndrome	early initiation		negative
acute myocardial infarction
atorvastatin
PROVE-IT, 2004	atorvastatin high dose	pravastatin	diabetic	early initiation	Low risk of bias	suggesting
aortic stenosis
atorvastatin
SALTIRE, 2005	atorvastatin	placebo	aortic stenosis		Low risk of bias	negative
rosuvastatin
ASTRONOMER, 2010	rosuvastatin	placebo	aortic stenosis		Low risk of bias	-
simvastatin
SEAS, 2008    NCT	ezetimibe+simvastatin	placebo	aortic stenosis		Low risk of bias	negative
CABG surgery
atorvastatin
Chello et al., 2006	preoperative atorvastatin	placebo			Low risk of bias	negative
Patti et al., 2006	preoperative atorvastatin	placebo			Low risk of bias	suggesting
simvastatin
Christenson, 1999	preoperative simvastatin	no treatment				negative
cardiovascular prevention
atorvastatin
ASCOT (diabetics sub group), 2003	atorvastatin	placebo	diabetic patients	primary prevention	Exploratory	negative
CARDS, 2004      NCT	atorvastatin	placebo	diabetic	type 2 diabetes	Low risk of bias	conclusive
Deutsche Diabetes Dialyse Studie (4D), 2005	atorvastatin	placebo			Low risk of bias	suggesting
ASPEN, 2006	atorvastatin	placebo	diabetic	type 2 diabetes	Low risk of bias	negative
ASPEN, 2006	atorvastatin	placebo	diabetic patients		Low risk of bias	negative
ASCOT, 2003	atorvastatin	placebo	at risk hypertensive	hypertensive patients	Low risk of bias	conclusive
MIRACL, 2001	atorvastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	suggesting
macin, 2005	atorvastatin	placebo	acute coronary syndrome	squamous NSCLC	Low risk of bias	-
SALTIRE, 2005	atorvastatin	placebo	aortic stenosis		Low risk of bias	negative
Mohler III, 2003	atorvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
SPARCL, 2006      NCT	atorvastatin	placebo	post stroke	cerebral vascular disease	Low risk of bias	suggesting
Strey, 2005	atorvastatin	placebo	heart failure			-
Mohler, 2003	atorvastatin	placebo	secondary prevention		Low risk of bias	-
ASPEN (primary prevention sub group), 2006	atorvastatin	placebo	diabetic	type 2 diabetes	Low risk of bias	negative
ASCOT (women subgroup) , 2003	Atorvastatin	placebo	women		Exploratory	negative
Colivicchi, 2002	atorvastatin	usual care	acute coronary syndrome	early initiation	Exploratory	negative
ESTABLISH, 2004	atorvastatin	usual care	acute coronary syndrome	early initiation	Exploratory	negative
GREACE, 2002	atorvastatin	usual care	secondary prevention		Risk of bias	suggesting
AVERT, 1999	atorvastatin high dose	angioplasty	secondary prevention		Risk of bias	negative
TNT (diabetic sub group), 2006	atorvastatin high dose	atorvastatin	diabetic patients	secondary prevention	Low risk of bias	suggesting
TNT, 2005            NCT	atorvastatin high dose	atorvastatin	secondary prevention		Low risk of bias	conclusive
Vascular basis, 2005	atorvastatin high dose	lovastatin	secondary prevention		Exploratory	negative
PROVE IT - TIMI 22, 2004	atorvastatin	pravastatin	acute coronary syndrome	early initiation	Low risk of bias	suggesting
REVERSAL, 2004	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	negative
PROVE-IT, 2004	atorvastatin high dose	pravastatin	diabetic	early initiation	Low risk of bias	suggesting
SAGE, 2007	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	suggesting
IDEAL, 2005        NCT	atorvastatin high dose	simvastatin	secondary prevention		Risk of bias	suggesting
bezafibrate
SENDCAP, 1998	bezafibrate	placebo		type 2 diabetes	Exploratory	suggesting
LEADER, 2002	bezafibrate	placebo			Low risk of bias	negative
LEADER trial, 2000	bezafibrate	placebo	Peripheral Arterial Disease		Low risk of bias	-
BECAIT, 1996	bezafibrate	placebo	secondary prevention		Exploratory	suggesting
BIP, 2000	bezafibrate	placebo	secondary prevention		Low risk of bias	negative
cerivastatin
Laufs, 2004	cerivastatin	placebo	heart failure		Low risk of bias	-
cholestyramine
STARS (cholestyramine), 1992	cholestyramine	control			Low risk of bias	negative
LRC, 1984	cholestyramine	placebo			Low risk of bias	negative
NHLBI (Brensike), 1984    NCT	cholestyramine	placebo	diabetic		Exploratory	negative
clofibrate
WHO clofibrate, 1978	clofibrate	placebo			Low risk of bias	suggesting
Cullen, 1974	clofibrate	placebo			Low risk of bias	-
Harrold, 1969	clofibrate	placebo		type 2 diabetes	Low risk of bias	-
Hanefeld, 1991	clofibrate	placebo		type 2 diabetes	Low risk of bias	negative
Begg, 1971	clofibrate	placebo	secondary prevention		Exploratory	negative
Acheson, 1972	clofibrate	placebo	secondary prevention	cerebral vascular disease	Exploratory	-
VA Neurology Section, 1974	clofibrate	placebo			Low risk of bias	-
CDP Clofibrate, 1975	clofibrate	placebo			Low risk of bias	suggesting
Scottish, 1971	clofibrate	placebo			Low risk of bias	negative
Newcastle, 1971	clofibrate	placebo			Low risk of bias	suggesting
SCOR, 1990	colestipol+clofibrate	placebo	diabetic		Low risk of bias	negative
colestipol
UCS (Dorr), 1978	colestipol	placebo			Low risk of bias	negative
Ryan, 1974	colestipol	placebo			Low risk of bias	-
Gundersen, 1976	colestipol	placebo			Low risk of bias	-
Ruoff, 1978	colestipol	placebo			Low risk of bias	negative
Gross, 1973	colestipol	placebo			Low risk of bias	-
diet
Veterans Ad. (Dayton), 1969	diet	usual diet			Low risk of bias	suggesting
MRFIT, 1982	diet	usual diet			Risk of bias	-
Hjermann, 1981	diet	usual diet			Risk of bias	-
Finnish Mental Hospital (Miettinen), 1985	diet	usual diet	primary prevention		Exploratory	-
WHO Collaborative, 1986	diet	usual diet			Low risk of bias	negative
Goteborg, 1986	diet	usual diet			Risk of bias	-
Rose, 1965	diet	usual diet			Exploratory	negative
Singh, 1992	diet	usual diet			Risk of bias	-
STARS (St Thomas, diet), 1992	diet	usual diet			Exploratory	negative
Los Angeles VA (Dayton), 1969	diet	usual diet			Low risk of bias	-
Ornish, 1990	diet	usual diet			Exploratory	negative
Kallio, 1979	diet	usual diet			Exploratory	-
MRC Soya, 1968	diet	usual diet			Risk of bias	negative
Woodhill, 1966	diet	usual diet			Low risk of bias	negative
Oslo Diet Heart Study (Leren), 1966	diet	usual diet			Risk of bias	suggesting
MRC low fat, 1965	diet	usual diet			Risk of bias	negative
WHI low fat, 2005    NCT	diet	usual diet			Exploratory	negative
Göteborg (Wilhelmsen), 1986	diet	usual diet			Low risk of bias	negative
Black, 1994	diet	usual diet			Risk of bias	negative
Minnesota coronary survey (Frantz), 1975	diet	usual diet			Exploratory	negative
Tuttle, 2008	low fat diet	mediterranean-style diet			Risk of bias	-
estrogen
Marmorstein, 1962	estrogen	placebo			Low risk of bias	-
Stamler, 1963	estrogen	placebo			Low risk of bias	-
CDP estrogen 5, 1975	estrogen	placebo			Low risk of bias	-
CDP estrogen 2.5, 1975	estrogen	placebo			Low risk of bias	-
VA Neurology Section (estrogen), 1966	estrogen	placebo			Low risk of bias	-
VA drugs (Estrogen or thyroxine), 1968	estrogen or thyroxine	placebo			Low risk of bias	suggesting
etofibrate
Emmerich, 2009	etofibrate	placebo	diabetic	type 2 diabetes	Exploratory	-
ezetimibe
SHARP, 2010      NCT	ezetimibe+simvastatin	placebo			Low risk of bias	suggesting
IMPROVE-IT, 2014      NCT	ezetimibe	placebo (on top statins)		early initiation	Low risk of bias	conclusive
Enhance, 2008	ezetimibe	placebo (on top statins)			Low risk of bias	-
SANDS, 2008      NCT	aggressive treatment	standard teatment	diabetic	type 2 diabetes	Exploratory	negative
ARBITER-HALTS 6, 2010	ezetimibe	niacin			Exploratory	-
fenofibrate
FIELD, 2005	fenofibrate	placebo	diabetic patients		Low risk of bias	suggesting
DAIS, 2001	fenofibrate	placebo	diabetic	type 2 diabetes	Exploratory	negative
FIELD, 2005	fenofibrate	placebo	diabetic	type 2 diabetes	Low risk of bias	suggesting
ACCORD lipid, 2010    NCT	fenofibrate	placebo (on top simvastatine)	diabetic patients		Low risk of bias	negative
fluvastatin
LIPS (diabetic sub group), 2002	fluvastatin	placebo	diabetic patients	secondary prevention	Exploratory	suggesting
ALERT (diabetic sub group), 2003	fluvastatin	placebo	diabetic patients		Low risk of bias	-
FLARE (elderly subgroup), 1999	fluvastatin	placebo	elderly	elderly	Low risk of bias	negative
LIPS (elderly subgroup), 2002	fluvastatin	placebo	elderly	elderly	Low risk of bias	suggesting
LIPS (sub groups), 2002	fluvastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
FLORIDA, 2002	fluvastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
LCAS, 1997	fluvastatin	placebo	secondary prevention		Exploratory	negative
Riegger et al., 1999	fluvastatin	placebo	secondary prevention		Low risk of bias	negative
FLARE, 1999	fluvastatin	placebo	secondary prevention		Exploratory	negative
BCAPS, 2001	fluvastatin	placebo	primary prevention	cerebral vascular disease	Low risk of bias	negative
ALERT, 2003	fluvastatin	placebo	CKD	kidney diseases	Low risk of bias	suggesting
LIPS, 2002	fluvastatin	placebo	secondary prevention		Low risk of bias	suggesting
ALERT, 2003	fluvastatin	placebo			Low risk of bias	negative
HYRIM, 2005	fluvastatin	placebo	hypertensive	hypertensive patients	Exploratory	negative
gemfibrozil
Helsinki (HHS), 1987	gemfibrozil	placebo			Low risk of bias	suggesting
HHS (diabetic sub group), 1987	gemfibrozil	placebo	diabetic patients	primary prevention	Low risk of bias	-
VA-HIT (diabetic sub group), 1999	gemfibrozil	placebo	diabetic patients	secondary prevention	Low risk of bias	negative
VA-HIT, 1999      NCT	gemfibrozil	placebo			Low risk of bias	suggesting
HHS (Frick)(secondary prev subgroup), 1993	gemfibrozil	placebo			Exploratory	negative
LOCAT, 1997	gemfibrozil	placebo			Exploratory	negative
lovastatin
AFCAPS/TexCAPS, 1998	lovastatin	placebo	primary prevention		Low risk of bias	conclusive
AFCAPS/TexCAPS (diabetic sub group), 1998	lovastatin	placebo	diabetic patients	primary prevention	Low risk of bias	-
CRISP 20mg, 1994    NCT	lovastatin	placebo	diabetic		Exploratory	-
ACAPS, 1994    NCT	lovastatin	placebo	secondary prevention	cerebral vascular disease	Exploratory	suggesting
CCAIT, 1994	lovastatin	placebo	secondary prevention		Exploratory	negative
MARS, 1993      NCT	lovastatin	placebo	secondary prevention		Exploratory	negative
Excel, 1991	lovastatin	placebo			Exploratory	negative
Weintraub, 1994	lovastatin	placebo	secondary prevention		Low risk of bias	negative
CRISP 40mg, 1994    NCT	lovastatin	placebo	diabetic		Exploratory	-
AFCAPS (women subgroup) , 1998	Lovastatin	placebo	women		Exploratory	negative
Sahni, 1991	lovastatin	usual care	secondary prevention		Risk of bias	negative
CLAPT, 1999	lovastatin	usual care	secondary prevention		Exploratory	negative
niacin
VA drugs, 1968	niacin	control			Low risk of bias	negative
Carlson (Stockholm), 1977	clofibtate+niacin	placebo	secondary prevention		Risk of bias	suggesting
CLAS, 1987	colestipol-niacin	placebo	secondary prevention		Exploratory	negative
CLAS, 1987	colestipol-niacin	placebo	Peripheral Arterial Disease		Exploratory	-
CDP niacin, 1975	niacin	placebo			Low risk of bias	suggesting
AIM-HIGH, 2011      NCT	niacin	placebo (on top statin)			Low risk of bias	negative
HPS 2-Thrive      NCT	niacin	placebo (on top statin)			Low risk of bias	negative
Oxford Niaspan Study, 2009    NCT	niacin	placebo (on top statin)			Exploratory	-
ARBITER 2, 2009	niacin	placebo (on top statin)			Exploratory	negative
HATS, 2001	niacin	placebo (on top statin)			Low risk of bias	negative
ARBITER 6-HALTS (niacin vs ezetimibe), 2009        NCT	niacin	ezetimibe			Exploratory	suggesting
policosanol
Castano, 2001	policosanol	control	diabetic		Low risk of bias	negative
Más, 1999	policosanol	control			Exploratory	negative
Batista, 1996	policosanol	control			Low risk of bias	-
pravastatin
MEGA, 2006        NCT	pravastatin	control	primary prevention		Risk of bias	suggesting
FAST Fukuoka pravastatin, 2002	pravastatin	control	primary prevention		Exploratory	-
WOSCOPS, 1995	pravastatin	placebo	primary prevention		Low risk of bias	conclusive
PROSPER diabetic (sub group), 2002	pravastatin	placebo	diabetic patients	secondary prevention	Low risk of bias	negative
LIPID (diabetic sub group), 1998	pravastatin	placebo	diabetic patients	secondary prevention	Low risk of bias	negative
CARE (diabetic sub group), 1998	pravastatin	placebo	diabetic patients	secondary prevention	Exploratory	suggesting
WOSCOPS (diabetic sub group), 1996	pravastatin	placebo	diabetic patients	primary prevention	Low risk of bias	-
PROSPER, 2002	pravastatin	placebo	secondary prevention	elderly	Low risk of bias	conclusive
CARE (elderly subgroup), 1998	Pravastatin	placebo	elderly	elderly	Low risk of bias	suggesting
LIPID (elderly sub group), 2001	Pravastatin	placebo	elderly	elderly	Low risk of bias	suggesting
PLAC I (elderly sub group), 1995	Pravastatin	placebo	elderly	elderly	Low risk of bias	negative
REGRESS (elderly subgroup), 1995	Pravastatin	placebo	elderly	elderly	Low risk of bias	negative
REGRESS, 1995	pravastatin	placebo	secondary prevention		Exploratory	suggesting
PMSG, 1993	pravastatin	placebo	primary prevention		Exploratory	negative
LIPID, 1998	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
CARE, 1996	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
LAMIL, 1997	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
RECIFE, 1999	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
PAIS, 2001	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	negative
PACT, 2004	pravastatin	placebo	acute coronary syndrome	early initiation	Low risk of bias	suggesting
CAIUS, 1996	pravastatin	placebo	primary prevention	cerebral vascular disease	Exploratory	negative
PREVEND IT, 2004	pravastatin	placebo	related disease	kidney diseases	Low risk of bias	negative
PLAC I, 1995	pravastatin	placebo	secondary prevention		Exploratory	suggesting
PLAC II, 1995	pravastatin	placebo	secondary prevention		Exploratory	negative
PACT, 2004	pravastatin	placebo	secondary prevention		Low risk of bias	negative
KAPS, 1995	pravastatin	placebo	primary prevention		Exploratory	negative
PHYLLIS, 2004	pravastatin	placebo	diabetic	cerebral vascular disease hypertensive patients	Exploratory	-
PROSPER (primary prevention subgroup), 2002	pravastatin	placebo	primary prevention	elderly	Exploratory	negative
ALLHAT (women subgroup) , 2002	Pravastatin	placebo	women		Exploratory	negative
MEGA (women subgroup) , 2006	Pravastatin	placebo	women		Exploratory	suggesting
GISSI P (diabetic sub group), 2000	pravastatin	usual care	diabetic patients	secondary prevention	Exploratory	-
ALLHAT-LLT (diabetic sub group), 2002	pravastatin	usual care	diabetic patients	secondary prevention	Exploratory	negative
ALLHAT, 2002      NCT	pravastatin	usual care	at risk hypertensive	hypertensive patients	Risk of bias	negative
L-CAD, 2000	pravastatin	usual care	acute coronary syndrome	early initiation	Exploratory	suggesting
PTT, 2002	pravastatin	usual care	acute coronary syndrome	early initiation	Exploratory	suggesting
GISSI Prevenzione, 2000	pravastatin	usual care	secondary prevention		Risk of bias	negative
KLIS, 2000	pravastatin	usual care	primary prevention		Risk of bias	-
PROVE IT TIMI 22 (diabetic sub group), 2006	pravastatin high dose	pravastatin	diabetic patients	secondary prevention	Low risk of bias	-
probucol
FATS Fukosawa (probucol), 2002	probucol	control	primary prevention		Exploratory	-
McCaughan, 1981	Probucol	placebo			Exploratory	-
Tardif, 1997	Probucol	placebo			Low risk of bias	negative
PQRST, 1994	probucol	placebo	Peripheral Arterial Disease		Exploratory	-
PQRST, 1994	probucol	placebo			Exploratory	-
rosuvastatin
JUPITER (elderly sub group), 2009	rosuvastatin	placebo	elderly	elderly	Low risk of bias	suggesting
JUPITER, 2008    NCT	rosuvastatin	placebo	primary prevention		Low risk of bias	conclusive
ASTRONOMER, 2010	rosuvastatin	placebo	aortic stenosis		Low risk of bias	-
METEOR, 2007      NCT	rosuvastatin	placebo	diabetic		Exploratory	negative
CORONA, 2007      NCT	rosuvastatin	placebo	heart failure		Low risk of bias	negative
Krum, 2007	rosuvastatin	placebo	heart failure		Low risk of bias	negative
GISSI-HF rosuvastatine, 2008      NCT	rosuvastatin	placebo	heart failure		Low risk of bias	negative
AURORA, 2009	rosuvastatin	placebo			Low risk of bias	negative
HOPE 3, 2016      NCT	rosuvastatin	placebo	primary prevention		Low risk of bias	conclusive
JUPITER (women subgroup) , 2008	Rosuvastatin	placebo	women		Exploratory	suggesting
simvastatin
Hong, 2005	simvastatin	control	heart failure		Risk of bias	negative
SEAS, 2008    NCT	ezetimibe+simvastatin	placebo	aortic stenosis		Low risk of bias	negative
HPS (diabetic sub group), 2002	simvastatin	placebo	diabetic patients		Low risk of bias	suggesting
4S (diabetic sub group), 1999	simvastatin	placebo	diabetic patients	secondary prevention	Low risk of bias	suggesting
HPS (diabetic primary prevention sub group), 2003	simvastatin	placebo	diabetic	type 2 diabetes	Exploratory	-
4S (elderly subgroup), 1997	simvastatin	placebo	elderly	elderly	Low risk of bias	suggesting
HPS (elderly subgroup), 2002	simvastatin	placebo	elderly	elderly	Low risk of bias	suggesting
HPS, 2002	simvastatin	placebo	secondary prevention		Low risk of bias	conclusive
4S, 1994	simvastatin	placebo	secondary prevention		Low risk of bias	conclusive
A to Z, 2004	simvastatin	placebo	acute coronary syndrome	early initiation		negative
CIS, 1997	simvastatin	placebo	secondary prevention		Exploratory	negative
Mondillo, 2003	simvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
Aronow , 2003	simvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
MAAS, 1994	simvastatin	placebo	secondary prevention		Exploratory	negative
Node, 2003	simvastatin	placebo	heart failure			negative
HPS (post troke sub group), 2004	simvastatin	placebo	post stroke	cerebral vascular disease	Low risk of bias	suggesting
HPS (women subgroup) , 2002	Simvastatin	placebo	women		Exploratory	suggesting
Landmesser, 2005	simvastatin	ezetimibe	heart failure			-
SEARCH, 2010    NCT	simvastatin high dose	simvastatin	secondary prevention		Low risk of bias	suggesting
thyroxine
CDP tyroxine, 1975	thyroxine	placebo			Low risk of bias	-
diabetes type 2
atorvastatin
ASCOT (diabetics sub group), 2003	atorvastatin	placebo	diabetic patients	primary prevention	Exploratory	negative
CARDS, 2004      NCT	atorvastatin	placebo	diabetic	type 2 diabetes	Low risk of bias	conclusive
ASPEN, 2006	atorvastatin	placebo	diabetic patients		Low risk of bias	negative
ASPEN (primary prevention sub group), 2006	atorvastatin	placebo	diabetic	type 2 diabetes	Low risk of bias	negative
TNT (diabetic sub group), 2006	atorvastatin high dose	atorvastatin	diabetic patients	secondary prevention	Low risk of bias	suggesting
ezetimibe
SANDS, 2008      NCT	aggressive treatment	standard teatment	diabetic	type 2 diabetes	Exploratory	negative
fenofibrate
FIELD, 2005	fenofibrate	placebo	diabetic patients		Low risk of bias	suggesting
ACCORD lipid, 2010    NCT	fenofibrate	placebo (on top simvastatine)	diabetic patients		Low risk of bias	negative
fluvastatin
LIPS (diabetic sub group), 2002	fluvastatin	placebo	diabetic patients	secondary prevention	Exploratory	suggesting
ALERT (diabetic sub group), 2003	fluvastatin	placebo	diabetic patients		Low risk of bias	-
gemfibrozil
HHS (diabetic sub group), 1987	gemfibrozil	placebo	diabetic patients	primary prevention	Low risk of bias	-
VA-HIT (diabetic sub group), 1999	gemfibrozil	placebo	diabetic patients	secondary prevention	Low risk of bias	negative
lovastatin
AFCAPS/TexCAPS (diabetic sub group), 1998	lovastatin	placebo	diabetic patients	primary prevention	Low risk of bias	-
pravastatin
PROSPER diabetic (sub group), 2002	pravastatin	placebo	diabetic patients	secondary prevention	Low risk of bias	negative
LIPID (diabetic sub group), 1998	pravastatin	placebo	diabetic patients	secondary prevention	Low risk of bias	negative
CARE (diabetic sub group), 1998	pravastatin	placebo	diabetic patients	secondary prevention	Exploratory	suggesting
WOSCOPS (diabetic sub group), 1996	pravastatin	placebo	diabetic patients	primary prevention	Low risk of bias	-
GISSI P (diabetic sub group), 2000	pravastatin	usual care	diabetic patients	secondary prevention	Exploratory	-
ALLHAT-LLT (diabetic sub group), 2002	pravastatin	usual care	diabetic patients	secondary prevention	Exploratory	negative
PROVE IT TIMI 22 (diabetic sub group), 2006	pravastatin high dose	pravastatin	diabetic patients	secondary prevention	Low risk of bias	-
simvastatin
HPS (diabetic sub group), 2002	simvastatin	placebo	diabetic patients		Low risk of bias	suggesting
4S (diabetic sub group), 1999	simvastatin	placebo	diabetic patients	secondary prevention	Low risk of bias	suggesting
familial hypercholesterolemia
ezetimibe
Enhance, 2008	ezetimibe	placebo (on top statins)			Low risk of bias	-
pactimibe
CAPTIVATE, 2009      NCT	pactimibe	placebo			Low risk of bias	-
torcetrapib
RADIANCE 1, 2007      NCT	torcetrapib	placebo			Exploratory	negative
heart failure
atorvastatin
Wojnicz, 2006	atorvastatin	control	heart failure			negative
Yamada, 2007	atorvastatin	control	heart failure			negative
Strey, 2005	atorvastatin	placebo	heart failure			-
Sola, 2006	atorvastatin	placebo	heart failure		Low risk of bias	negative
cerivastatin
Laufs, 2004	cerivastatin	placebo	heart failure		Low risk of bias	-
rosuvastatin
CORONA, 2007      NCT	rosuvastatin	placebo	heart failure		Low risk of bias	negative
Krum, 2007	rosuvastatin	placebo	heart failure		Low risk of bias	negative
GISSI-HF rosuvastatine, 2008      NCT	rosuvastatin	placebo	heart failure		Low risk of bias	negative
simvastatin
Hong, 2005	simvastatin	control	heart failure		Risk of bias	negative
Node, 2003	simvastatin	placebo	heart failure			negative
Landmesser, 2005	simvastatin	ezetimibe	heart failure			-
hypertension
atorvastatin
ASCOT, 2003	atorvastatin	placebo	at risk hypertensive	hypertensive patients	Low risk of bias	conclusive
fluvastatin
HYRIM, 2005	fluvastatin	placebo	hypertensive	hypertensive patients	Exploratory	negative
peripheral vascular diseases
atorvastatin
Mohler III, 2003	atorvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
bezafibrate
LEADER trial, 2000	bezafibrate	placebo	Peripheral Arterial Disease		Low risk of bias	-
niacin
CLAS, 1987	colestipol-niacin	placebo	Peripheral Arterial Disease		Exploratory	-
probucol
PQRST, 1994	probucol	placebo	Peripheral Arterial Disease		Exploratory	-
simvastatin
HPS (sub group), 2002	simvastatin	placebo	Peripheral Arterial Disease		Low risk of bias	-
Mondillo, 2003	simvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
Aronow , 2003	simvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
post myocardial infarction
atorvastatin
TNT, 2005            NCT	atorvastatin high dose	atorvastatin	secondary prevention		Low risk of bias	conclusive
Vascular basis, 2005	atorvastatin high dose	lovastatin	secondary prevention		Exploratory	negative
REVERSAL, 2004	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	negative
SAGE, 2007	atorvastatin high dose	pravastatin	secondary prevention		Exploratory	suggesting
IDEAL, 2005        NCT	atorvastatin high dose	simvastatin	secondary prevention		Risk of bias	suggesting
bezafibrate
BECAIT, 1996	bezafibrate	placebo	secondary prevention		Exploratory	suggesting
BIP, 2000	bezafibrate	placebo	secondary prevention		Low risk of bias	negative
diet
Tuttle, 2008	low fat diet	mediterranean-style diet			Risk of bias	-
ezetimibe
IMPROVE-IT, 2014      NCT	ezetimibe	placebo (on top statins)		early initiation	Low risk of bias	conclusive
gemfibrozil
VA-HIT, 1999      NCT	gemfibrozil	placebo			Low risk of bias	suggesting
niacin
Carlson (Stockholm), 1977	clofibtate+niacin	placebo	secondary prevention		Risk of bias	suggesting
pravastatin
PACT, 2004	pravastatin	placebo	secondary prevention		Low risk of bias	negative
LIPID, 1998	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
CARE, 1996	pravastatin	placebo	secondary prevention		Low risk of bias	conclusive
simvastatin
4S, 1994	simvastatin	placebo	secondary prevention		Low risk of bias	conclusive
post stroke
atorvastatin
SPARCL, 2006      NCT	atorvastatin	placebo	post stroke	cerebral vascular disease	Low risk of bias	suggesting
simvastatin
HPS (post troke sub group), 2004	simvastatin	placebo	post stroke	cerebral vascular disease	Low risk of bias	suggesting